Business
Canopy Growth announces completion of study on the long-term effects of CBD
Canopy Growth announces completion of study on the long-term effects of CBD Can...
About this update from Canopy Growth Corporation
[{"type":"text","content":"\n \n \n \n Canopy Growth announces completion of study on the long-term effects of CBD\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n SMITHS FALLS, ON, Nov. 23, 2020\n \n \n \n \n \n Study represents the first research completed on the long-term toxicity and lifespan effects of cannabidiol in the preclinical model\n \n C. elegans\n \n \n \n \n \n SMITHS FALLS, ON\n \n ,\n \n Nov. 23, 2020\n \n /CNW/ - Canopy Growth Corporation (\"Canopy Growth\" or the \"Company\") (TSX: WEED) (NASDAQ: CGC) and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model\n \n C. elegans.\n \n \n \n \n \n \n \n \n \n \n The study was commissioned to evaluate the solubility, stability, acute toxicity, thermotolerance, and effects on lifespan of CBD in\n \n C. elegans\n \n as part of Canopy Growth's ongoing commitment to provide the data required to support and influence public policy through research. To the best of the Company's knowledge, this study represents the first long-term toxicity and lifespan research regarding the effects of chronic exposure to cannabidiol – one of the cannabinoids found in cannabis.\n \n \n Acute and long-term exposure studies of CBD at physiologically relevant concentrations were studied in the worm model\n \n Caenorhabditis elegans\n \n (\n \n C. elegans\n \n ) on the basis that 60-80% of their genes are shared with humans, and their comparatively short lifespan of 2-3 weeks makes such studies feasible. In the\n \n C. elegans\n \n model, which is recognized as a valid model for this kind of research, CBD did not demonstrate any degree of acute or life-long toxicity or related liabilities at physiological concentrations. Instead, CBD extended mean lifespan up to 18% and increased late-stage life activity by up to 206% compared to the untreated controls within the study.\n \n \n \"Despite widespread use of CBD, no life-long toxicity studies had been conducted ...